Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100180 | 0.88 | F10 (0.88) | F10F2 | |
| SCHEMBL14176198 | 0.86 | F10 (0.82) | F10F2 | |
| SCHEMBL5097164 | 0.85 | F10 (0.62) | F10F2 | |
| SCHEMBL5100138 | 0.82 | F10 (0.88) | F10F2 | |
| SCHEMBL5093526 | 0.81 | F10 (1.00) | F10F2 | |
| SCHEMBL5099954 | 0.81 | F10 (0.87) | F10F2 | |
| SCHEMBL14176323 | 0.81 | F10 (0.77) | F10F2 | |
| SCHEMBL14176311 | 0.80 | F10 (0.76) | F10F2 | |
| SCHEMBL14176174 | 0.80 | F10 (0.81) | F10F2 | |
| SCHEMBL14176184 | 0.79 | F10 (0.82) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381732-B2 | Pyrazolobenzamides and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1812403-A2 | PYRAZOLOBENZAMIDES AND DERIVATIVES AS FACTOR XA INHIBITORS | Brystol-Myers Squibb Company (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006047528-A2 | PYRAZOLOBENZAMIDES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060089496-A1 | Pyrazolobenzamides and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089496-A1 | Pyrazolobenzamides and derivatives as factor Xa inhibitors | F12, TFPI, PRSS1 | F10 50/4885F2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.